Alexia

disease
On this page

Also known as acquired alexiaacquired dyslexiaacquired global dyslexiaacquired reading disabilitiesacquired reading disabilityacquired spelling dyslexiaacquired Word blindnessacquired Word Blindnessesalexia, acquiredblindness, acquired WordBlindnesses, acquired Worddisabilities, acquired readingdisability, acquired readingdyslexia, acquired globaldyslexia, acquired spellingglobal dyslexia, acquiredreading disabilities, acquiredreading disability, acquiredspelling dyslexia, acquiredWord blindness, acquired

Summary

Alexia (MONDO:0001712) is a disease and 4 clinical trials. A subtype of visual agnosia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namealexia
Mondo IDMONDO:0001712
MeSHD004411
DOIDDOID:13417
ICD-11262295178
UMLSC0002018
MedGen1809
GARD0027588
Is cancer (heuristic)no

Also known as: acquired alexia · acquired dyslexia · acquired global dyslexia · acquired reading disabilities · acquired reading disability · acquired spelling dyslexia · acquired Word blindness · acquired Word Blindnesses · alexia, acquired · blindness, acquired Word · Blindnesses, acquired Word · disabilities, acquired reading · disability, acquired reading · dyslexia, acquired global · dyslexia, acquired spelling · global dyslexia, acquired · reading disabilities, acquired · reading disability, acquired · spelling dyslexia, acquired · Word blindness, acquired (+1 more)

Disease family

This is a subtype of visual agnosia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disordermental disordervisual agnosiaalexia

Related subtypes (6): apperceptive agnosia, associative visual agnosia, color agnosia, form agnosia, topographical agnosia, alexia without agraphia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified4

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04991519Not specifiedACTIVE_NOT_RECRUITINGBrain-based Understanding of Individual Language Differences After Stroke
NCT06700005Not specifiedRECRUITINGReadMap: Reading in Stroke Alexia and Typical Aging
NCT03662243Not specifiedCOMPLETEDTreatment for Reading and Writing Deficits Following Acquired Brain Injury
NCT04849091Not specifiedUNKNOWNClinical Effectiveness of iReadMore for People With Alexia

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.